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Incidence of gynecologi-
cal malignancy among the 
Saudi population
To the Editor: In the past 20 
years, women’s health research has 
increased and resulted in scien-
tific knowledge that has influenced 
practice, policy, and program de-
velopment. The five most common 
types of cancers affecting the female 
genital tract ae endometrial, ovarian, 
cervical, vulvar and vaginal cancer. 
Gynecological malignancies are a 
common types of cancer in Saudi 
women, but there is no clear data 
to estimate the incidence of gyne-
cological malignancies among our 
population. Having these data may 
influence our practice, policy, and 
program development for these pa-
tients.
We reviewed and performed ad-
ditional analysis of the data from 
the Saudi Cancer Registry between 
January 1999 to December 2008, in-
cluding all females with genital tract 
malignancy (Figure 1). An Ovid 
Medline review of papers about gy-
necological cancer and risk factors in 
the gulf region was also done. 
For the period between 1999-
2008, 30 726 cases of female can-
cer were diagnosed. Of these, we 
found that 2943 cases (9.6%) were 
gynecological malignancies. Ovarian 
cancer was the most common female 
genital tract malignancy accounting 
for 1036 cases (35.2%) of all gyne-
cological malignancies and repre-
senting 3.4% of all female cancers, 
followed by 1007 cases (34.21%) 
endometrial cancer representing 
3.3 % of all female cancers. cervi-
cal cancer was the third most com-
mon gynecological malignancy with 
811 cases (27.6% ) of gynecological 
malignancies among Saudi women 
and 2.6% of all female cancer cases. 
Vulvar cancer accounted for 61 cases 
or 2% of gynecologic malignancies 
and 0.2% of all female malignancies. 
Figure 1. genital tract malignancies from the Saudi Cancer registry, January 1999 to 
december 2008.
The least common cancer of female 
genital tract was vaginal cancer, with 
28 cases (0.95 %) representing 0.1% 
of female cancers.
In 2000, there were more than 
4.7 million cases of cancer in women 
worldwide, 54% of which occurred 
in underdeveloped countries.1 
Gynecologic cancers, including 
cancer of the endometrium, ovary, 
vulva, vagina, placenta and cervix, 
accounted for 8% of all female pri-
mary tumors worldwide while our 
data showed that the incidence of 
gynecologic cancer is slightly higher 
than the international incidence 
(9.6%) even with exclusion of gesta-
tional trophoblastic neoplasm from 
our data. In the developed coun-
tries, ovarian cancer is the second 
most common gynecologic cancer 
after endometrial cancer with inci-
dence of 31% of all female genital 
tract malignancies and 3% of all fe-
male malignancies.2 The statistics in 
Saudi Arabia showed that ovarian 
cancer is the most common gyneco-
logic malignancy with an incidence 
comparable with the international 
incidence (35.2%). The high parity 
among Saudi women did not seem 
to decrease the incidence of ovarian 
cancer. 
Endometrial cancer is the sev-
enth most common malignancy 
affecting women worldwide, with 
almost 190 000 cases annually.4 It 
is the most common female geni-
tal tract malignancy in Canada, 
accounting for 43% of all female 
genital malignancies, which is 
comparable with our incidence. In 
2008, cervical cancer accounted for 
9 percent (529 800) of the total 
new cancer cases among females 
worldwide. The incidence in Saudi 
Arabia is lower than the interna-
tional incidence (2.64%), which can 
be explained by the lack of a screen-
ing program for cervical cancer re-
flecting an underestimation of the 
disease. Worldwide, primary cancer 
of the vulva and vagina comprises 
approximately 3 and 4 percent, 
respectively, of all malignancies of 
the female genital tract, which is 
comparable with our population. 
Comparing our data on gyneco-
logical malignancies incidence with 
Qatar data, we found that the in-
cidence of gynecological malignan-
cies in Saudi Arabia is higher (9.6% 
Vs 6.9%).5 The incidence of ovar-
ian cancer was 22.9% as a second 
most common gynecological malig-
nancy after cervical cancer (54.9%) 
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gynaecological malignancies in Qatar.
followed by endometrial cancer 
(16.0%).
In conclusion, gynecological 
malignancies are common in Saudi 
Arabia. Further study is needed to 
assess the risk factors for ovarian 
and endometrial cancer in Saudi 
Arabia with more specification 
about histological types. The need 
for national screening program for 
cervical cancer is raised and we need 
to improve our reporting system for 
cancer cases.
These findings provide an ad-
equate foundation for planning of 
gynecological cancer education, 
screening programs and resource al-
location in Saudi Arabia.
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Bone mineral density in 
ex-thalassemic pediatric 
patients
To the Editor: In b-thalassemia 
major, extreme bone marrow hyper-
plasia, bone expansion, extramed-
ullary hematopoiesis and growth 
retardation are present due to inef-
fective erythropoiesis.1 Bone de-
formity, delayed bone age, growth 
failure, rickets, scoliosis, spinal de-
formities, nerve compression, osteo-
penia and osteoporosis,2 are some 
of bone disorders that thalassemic 
patients suffer from. 
Even in well-treated patients, 
osteoporosis and low bone mass are 
common problem that could cause 
pathologic fracture and further 
complications in the course of the 
disease. Allogeneic hematopoietic 
stem cell transplantation (HSCT) 
has emerged as a cornerstone in the 
development of cell-based therapies 
in these patients that may provide 
them with disease-free survival.3 
The risks associated with HSCT 
are substantial and should be con-
sidered. Low bone density is one of 
the common problems in HSCT-
treated thalassemic patients. It can 
be caused by various factors in-
cluding gonadal failure, prolonged 
immobility, decreased osteopro-
genitor cells, use of conditioning 
regimens, vitamin D deficiency, sec-
ondary hyperparathyroidism, and 
cyclosporine-corticosteroid ther-
apy for graft-versus-host disease 
(GVHD).4 After Italy, Iran has the 
largest population of transplanted 
thalassemic patients. In this regard, 
we aimed to monitor the bone sta-
tus of HSC transplanted patients 
before and after transplantation.5
In our center, the policy is to 
transplant all transfusion-depen-
dent beta-thalassemia major pa-
tients who had HLA-identical 
related donors, regardless of their 
disease severity. We enrolled 20 
patients from three classes of thal-
assemia who were candidates for 
HSCT in this study. The mean 
(SD) age of patients was 7.4 (3.8) 
years and the female:male ratio 
was 1:1. The bone mineral density 
(BMD) of participants was tested 
at baseline (before transplanta-
tion), and at 6 and 12 months 
post-transplant using a Norland 
XR-46 device (Norland Corp, Fort 
Arkinson, WI, USA). Prophylaxis 
for GVHD included corticosteroid 
and cyclosporine. All the 20 pa-
tients in the study who completed 
the three phases of the study were 
free from any transfusion for at least 
1 year after HSCT. After discharge, 
patients were followed in our post-
HSCT clinic weekly for the first 
month, then every two weeks until 
day 100, and thereafter according to 
the condition of each patient until 
one year.
The term “low bone mineral 
density for age” is a criterion for 
low bone mass in children, and is 
described as a child with a z score 
<-2. None of our patients met 
this criteria, either before or after 
transplant. No significant change in 
BMD was detected after transplant 
(both 6 and 12 months follow-up) 
in the three groups of our patients. 
Indeed, no remarkable association 
between corticosteroid usage and 
BMD was observed. In ex-thalasse-
